Stocks Health care PALI
NASDAQ · Health carePalisade Bio, Inc. (PALI)
Palisade Bio, Inc. brought in $500K of revenue over the twelve months to June 30, 2026. It posted a net loss of $31.9M. At June 30, 2026 it held $125.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about Palisade Bio, Inc.
- Net worth
- Palisade Bio, Inc. has a market value (market cap) of $196.9M at the latest share price, and shareholders' equity of $121.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $16.8M. Over the 12 months to June 30, 2026: revenue $500K, net loss $31.9M.
- Cash flow
- In fiscal 2025 operations used $10.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Palisade Bio, Inc. does
Palisade Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker PALI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$16.8M | -$0.30 | n/a |
| 2024 | $0 | -$14.4M | -$10.19 | -$12.2M |
| 2023 | $300K | -$12.3M | -$27.01 | -$11.1M |
| 2022 | $0 | -$14.3M | -$248.04 | -$13.4M |
| 2021 | n/a | -$26.6M | -$2,547.04 | -$14.8M |
| 2020 | $13.5K | -$10.3M | -$2,794.99 | -$4.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Palisade Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake changed SCHEDULE 13G/A
- October 30, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- August 10, 2026
- July 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 11, 2026
- June 10, 2026
- May 27, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Palisade Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $28.8K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 19, 2026 | Capers Julien E.See Remarks | Received as pay | 787,300 | - |
| October 6, 2026 | Finley John DavidCEO CFO, Director | Exercised options | 3,227,384 | - |
| October 6, 2026 | Finley John DavidCEO CFO, Director | Shares withheld for tax | 1,411,982 | $2.1M |
| October 6, 2026 | Jones Mitchell LawrenceSee Remarks | Exercised options | 2,620,850 | - |
| October 6, 2026 | Jones Mitchell LawrenceSee Remarks | Shares withheld for tax | 1,031,102 | $1.5M |
| October 2, 2026 | Williams Donald AllenDirector | Bought | 10,000 | $14.6K |
| October 1, 2026 | Williams Donald AllenDirector | Bought | 10,000 | $14.2K |
| August 19, 2026 | Finley John DavidCEO, CFO, Director | Gave as a gift | 88,400 | - |
Who owns PALI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive with 1 related filers | 9.99% | December 8, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | May 15, 2026 |
| Soleus Capital Master Fund, L.P.13G, passive with 5 related filers | 8.6% | November 9, 2026 |
| Perceptive Advisors LLC13G, passive with 2 related filers | 7.9% | May 15, 2026 |
| Octagon Capital Advisors LP13G, passive with 2 related filers | 6.4% | February 10, 2026 |
| Vanguard Capital Management13G, passive | 5.16% | October 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 124 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Soleus Capital Management, L.P. | 13,063,687 | new |
| B Group, Inc. | 11,414,285 | 0 |
| Ameriprise Financial Inc | 11,081,434 | -428,886 |
| Jupiter Topco LLC | 10,689,452 | new |
| BlackRock, Inc. | 10,436,760 | +8,560,420 |
| Octagon Capital Advisors LP | 10,276,317 | 0 |
| Perceptive Advisors LLC | 8,425,065 | -503,084 |
| RA Capital Management, L.P. | 7,124,116 | 0 |
| Franklin Resources Inc | 5,785,189 | 0 |
| Point72 Asset Management, L.P. | 5,253,403 | +4,841,631 |
| Boxer Capital Management, LLC | 4,799,875 | 0 |
| Adage Capital Partners GP, L.L.C. | 4,500,000 | 0 |
| Eversept Partners, LP | 4,182,785 | -804,714 |
| Geode Capital Management, LLC | 3,760,485 | +2,214,245 |
| Wellington Management Group Llp | 3,703,936 | +799,025 |
| Goldman Sachs Group Inc | 3,578,020 | -1,795,931 |
| Federated Hermes, Inc. | 3,136,607 | 0 |
| Squadron Capital Management LLC | 3,000,000 | 0 |
| Propel Bio Management, LLC | 2,582,388 | +1,467,388 |
| Vestal Point Capital, LP | 2,500,000 | 0 |
Insiders
8 insiders reported holding 8,119,155 shares in total, about $9.2M at the last price.
| Holder | Shares |
|---|---|
| Finley John DavidCEO, CFO, Director | 2,033,14188,451 held indirectly |
| Jones Mitchell LawrenceSee Remarks | 1,683,757 |
| Williams Donald AllenDirector | 1,590,294 |
| Capers Julien E.See Remarks | 787,300 |
| Wei BinxianDirector | 613,355 |
| Chuang EmilDirector | 612,500 |
| Baltera Robert Jr.Director | 461,904 |
| Zwick Jordan MichaelDirector | 336,904 |
Questions about PALI
What does Palisade Bio, Inc. do?
Palisade Bio, Inc. is a company in the Health care sector, listed on NASDAQ as PALI. Its shares trade on NASDAQ under the ticker PALI.
What is Palisade Bio, Inc.'s net worth?
Palisade Bio, Inc. has a market value (market cap) of $196.9M at the latest share price, and shareholders' equity of $121.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Palisade Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $31.9M on revenue of $500K.
How much revenue does Palisade Bio, Inc. make?
Over the twelve months to June 30, 2026 Palisade Bio, Inc. reported revenue of $500K.
When did Palisade Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from November 9, 2026.
Similar companies
Compare PALI with
Follow PALI
Get an email when Palisade Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Palisade Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.